A Mixed Bag Of Potential? Select Medical Holdings Corporation (SEM), Aecom (ACM) and Halozyme Therapeutics, Inc. (HALO)

Posted by admin May 13, 2015 0 Comment 553 views

New York, NY – GDP INSIDER  –  05/13/2014.

This article discusses three companies: Select Medical Holdings Corporation (NYSE:SEM), Aecom (NYSE:ACM) and Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Select Medical Holdings Corporation (NYSE:SEM) continued to decline yesterday with the stock closing down 3.20% or $0.49 to close the day at $14.80 on light trading volume of 0.664 million, compared to its three month average trading volume of 0.920 million. Despite the loss, the stock is trading 31.05% above its 52 week low of $11.29 and 7.30% above its 200 day moving average of $13.79. However, with RSI of 49.94 and bearish MACD divergence, the stock may continue to fall in the near term. At this time, it is a risky buying opportunity, but one that may be worth it over the medium term.

Do Select Medical Holdings Corporation Fundamentals Support Significant Medium Term Gains? Click Here For Free SEM Analysis.

Aecom (NYSE:ACM) suffered a decline yesterday as the stock lost $0.78 to finish the day at a closing price of $30.97, a 2.46% decrease in value from its previous closing price of $31.75. The company’s trading volume spiked to a figure of 3,914,738, which is significantly higher than its three month average trading volume of 1.49 million following the announcement of its fiscal second quarter results yesterday. The company reported earnings per share of $0.58, which topped analysts’ estimate of $0.54 per share by $0.04 per share. The US based professional technical and management support services provider around the world posted revenue of $4.51 billion for the quarter, which missed analysts’ estimate of $4.57 billion by $0.06 billion. With RSI of 41.52, it is a hold for now.

Does Aecom Offer A Profitable Investment Opportunity? Click Here For Free ACM Analysis.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares jumped yesterday as the stock gained 4.23% or $0.65 to close the day at $16.02 on slightly lower than average trading volume of 1.256 million, compared to its three month average trading volume of 1.42 million. The stock has seen its value increase by 101.51% over the past one year, far outperforming the S&P 500 index which is up only 11.15% for the same period. With quarterly revenue growth of 66.70% year over year and RSI of 54.41, the stock has plenty of upside potential to achieve or exceed its one year price target estimate of $18.63, making it a solid hold.

Is It Now A Good Time To Invest In Halozyme Therapeutics, Inc? Make A Wise Investment Decision With Our Free HALO Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment